Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS.

Details

Serval ID
serval:BIB_C12CEF723BE2
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS.
Journal
Annals of oncology
Author(s)
Park K., Vansteenkiste J., Lee K.H., Pentheroudakis G., Zhou C., Prabhash K., Seto T., Voon P.J., Tan DSW, Yang JCH, Wang J., Babu K.G., Nakayama Y., Alip A., Chua KLM, Cheng J.C., Senan S., Ahn Y.C., Kim T.Y., Ahn H.K., Peters S., Yoshino T., Douillard J.Y.
ISSN
1569-8041 (Electronic)
ISSN-L
0923-7534
Publication state
Published
Issued date
02/2020
Peer-reviewed
Oui
Volume
31
Number
2
Pages
191-201
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of early and locally-advanced non-small-cell lung cancer (NSCLC) was published in 2017, and covered the diagnosis, staging, management and treatment of both early stage I and II disease and locally-advanced stage III disease. At the ESMO Asia Meeting in November 2018, it was decided by both the ESMO and the Korean Society of Medical Oncology (KSMO) to convene a special face-to-face guidelines meeting in 2019 in Seoul. The aim was to adapt the ESMO 2017 guidelines to take into account potential differences related to ethnicity, cancer biology and standard practices associated with the treatment of locally-advanced, unresectable NSCLC in Asian patients. These guidelines represent the consensus opinions reached by those experts in the treatment of patients with lung cancer who represented the oncology societies of Korea (KSMO), China (CSCO), India (ISMPO), Japan (JSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence, and it was independent of both local current treatment practices and the treatment availability and reimbursement situations in the individual participating Asian countries.
Keywords
ESMO guidelines, NSCLC, Pan-Asian, consensus, locally-advanced, unresectable
Pubmed
Open Access
Yes
Create date
23/01/2020 15:25
Last modification date
21/11/2020 6:26
Usage data